Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.

Trial Profile

Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2009

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jun 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Actual end date (Feb 2005) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top